Vimarsana.com

Latest Breaking News On - Percyh carter - Page 4 : vimarsana.com

Blueprint Medicines (NASDAQ:BPMC) Given New $83.00 Price Target at The Goldman Sachs Group

Blueprint Medicines (NASDAQ:BPMC) Given New $83.00 Price Target at The Goldman Sachs Group
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

United-states
Percyh-carter
Morgan-stanley
Associates-corp
Lazard-asset-management
Blueprint-medicines-company-profile
Goldman-sachs-group
Nisa-investment-advisors
Bessemer-group-inc
Blueprint-medicines-corporation
Barclays

Blueprint Medicines Co. (NASDAQ:BPMC) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Shares of Blueprint Medicines Co. (NASDAQ:BPMC – Get Free Report) have been given a consensus recommendation of “Moderate Buy” by the fifteen research firms that are covering the firm, Marketbeat reports. Two analysts have rated the stock with a sell recommendation, three have given a hold recommendation, nine have issued a buy recommendation and one […]

United-states
Percyh-carter
Securities-exchange-commission
Barclays
Wells-fargo-company
Blueprint-medicines-corporation
Linden-thomas-advisory-services
Morgan-stanley
Blueprint-medicines-co
Nasdaq
Corton-capital-inc

Blueprint Medicines Co. (NASDAQ:BPMC) Shares Acquired by Nisa Investment Advisors LLC

Nisa Investment Advisors LLC grew its stake in Blueprint Medicines Co. (NASDAQ:BPMC – Free Report) by 158.0% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,605 shares of the biotechnology company’s stock after buying an additional 983 shares during the quarter. […]

United-states
Percyh-carter
Nisa-investment-advisors
Morgan-stanley
Linden-thomas-advisory-services
Tekla-capital-management
Goldman-sachs-group
Blueprint-medicines-co
Emerald-advisers
Securities-exchange-commission
Nasdaq

Blueprint Medicines (NASDAQ:BPMC) Upgraded at Wells Fargo & Company

Wells Fargo & Company upgraded shares of Blueprint Medicines (NASDAQ:BPMC – Free Report) from an equal weight rating to an overweight rating in a research note published on Monday morning, Marketbeat.com reports. They currently have $82.00 price objective on the biotechnology company’s stock, up from their previous price objective of $55.00. A number of other […]

United-states
Los-angeles
California
Montreal
Quebec
Canada
Percyh-carter
Blueprint-medicines-company-profile
Wells-fargo-company
Securities-exchange-commission
Barclays

Blueprint Medicines Co. Expected to Post Q1 2024 Earnings of ($2.24) Per Share (NASDAQ:BPMC)

Blueprint Medicines Co. Expected to Post Q1 2024 Earnings of ($2.24) Per Share (NASDAQ:BPMC)
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

United-states
Percyh-carter
Us-bancorp
Blueprint-medicines-corporation
Metlife-investment-management
Raymond-james-associates
Nasdaq
Wells-fargo-company
Blueprint-medicines-company-profile
Blueprint-medicines-co
Blackrock-inc

vimarsana © 2020. All Rights Reserved.